Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
Sign Up to like & getrecommendations! Published in 2022 at "RMD Open"
DOI: 10.1136/rmdopen-2021-001669
Abstract: Objectives To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in China. Methods In this phase 3, open-label extension period, eligible completers of study BEL113750 (NCT01345253) received intravenous… read more here.
Keywords: belimumab patients; year; long term; efficacy belimumab ... See more keywords